REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company, today announced that its Board of Directors has approved an increase to the company’s current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
